SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BARALDI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.107
AS - Asia 1.495
EU - Europa 1.303
SA - Sud America 332
AF - Africa 50
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.040
SG - Singapore 500
CN - Cina 483
DE - Germania 280
BR - Brasile 279
IT - Italia 245
PL - Polonia 204
VN - Vietnam 130
TR - Turchia 122
HK - Hong Kong 121
GB - Regno Unito 120
UA - Ucraina 104
SE - Svezia 88
FI - Finlandia 69
RU - Federazione Russa 68
FR - Francia 38
CA - Canada 36
IN - India 28
ZA - Sudafrica 27
BE - Belgio 26
ID - Indonesia 26
MX - Messico 25
BD - Bangladesh 19
AR - Argentina 16
NL - Olanda 14
AT - Austria 13
ES - Italia 13
JP - Giappone 11
CL - Cile 10
EG - Egitto 10
IQ - Iraq 10
EC - Ecuador 7
UZ - Uzbekistan 7
CZ - Repubblica Ceca 6
PK - Pakistan 6
AU - Australia 5
CO - Colombia 5
SA - Arabia Saudita 5
TW - Taiwan 5
UY - Uruguay 5
VE - Venezuela 5
KE - Kenya 4
PY - Paraguay 4
BG - Bulgaria 3
IL - Israele 3
JO - Giordania 3
LT - Lituania 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
EU - Europa 2
IR - Iran 2
MA - Marocco 2
NP - Nepal 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GL - Groenlandia 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
KH - Cambogia 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MC - Monaco 1
MK - Macedonia 1
MN - Mongolia 1
NA - Namibia 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.295
Salva come PNG Salva come JPEG
Città #
Dallas 770
Ashburn 419
Fairfield 360
Woodbridge 354
Singapore 313
Ann Arbor 207
Warsaw 200
Chandler 178
Beijing 175
Houston 172
Seattle 144
Wilmington 138
Santa Clara 137
Jacksonville 123
Cambridge 119
Hong Kong 118
Ferrara 108
Munich 74
Los Angeles 68
Izmir 58
New York 45
Shanghai 41
Milan 40
Nanjing 36
Princeton 34
Dong Ket 31
Ho Chi Minh City 28
Boardman 27
London 27
Brussels 26
Turku 25
San Diego 23
São Paulo 23
Hanoi 22
Bremen 19
Helsinki 19
Addison 18
Jakarta 18
Brooklyn 16
Asnières-sur-Seine 14
Shenyang 14
Chicago 13
Nanchang 13
Orem 12
Stockholm 12
Toronto 12
Council Bluffs 11
Denver 11
Jiaxing 11
Mexico City 11
Tokyo 11
Changsha 10
Frankfurt am Main 10
Hebei 10
Montreal 10
Phoenix 10
Poplar 10
Amsterdam 9
Atlanta 9
Des Moines 9
Johannesburg 9
Moscow 9
Querétaro 9
Cairo 8
Chennai 8
Falls Church 8
San Jose 8
Belo Horizonte 7
Brasília 7
Buffalo 7
Curitiba 7
Hefei 7
Mcallen 7
Redwood City 7
Rio de Janeiro 7
San Francisco 7
Tianjin 7
Washington 7
Ankara 6
Baghdad 6
Boston 6
Cape Town 6
Guangzhou 6
Manchester 6
Montréal 6
Norwalk 6
Tashkent 6
Auburn Hills 5
Columbus 5
Da Nang 5
Guarulhos 5
Haiphong 5
Jinan 5
Kunming 5
Montevideo 5
Mumbai 5
Nuremberg 5
Salvador 5
The Dalles 5
Zhengzhou 5
Totale 5.240
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 1.175
Design and Synthesis of New A2B Adenosine Receptor Antagonists 267
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 261
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 242
2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition 241
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 238
A3 adenosine receptor antagonists: History and future perspectives 236
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 234
7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation 227
Design, synthesis and biological evaluation of 3-substituted-2-oxindole hybrid derivatives as novel anticancer agents 227
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3’,4’,5’-Trimethoxyphenyl)-2-Aryl-1H-Imidazole 223
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 216
Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents 210
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 209
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 206
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 201
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 192
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 187
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 186
Synthesis and Biological Evaluation of Novel Allosteric Enhancers of the A1 Adenosine Receptor Based on 2-Amino-3-(4’-Chlorobenzoyl)-4-Substituted-5-Arylethynyl Thiophene 180
Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors 160
Synthesis and biological evaluation of alpha-bromoacryloylamido indolyl pyridinyl propenones as potent apoptotic inducers in human leukaemia cells 136
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 123
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 123
null 121
3-Aryl/Heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization 119
null 118
Adenosine Receptors in Colon Carcinoma Tissues and Colon Tumoral Cell Lines: Focus on the A3 Adenosine Subtype 115
Novel 1,3-Dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as Potent and Selective A2B Adenosine Receptor Antagonists 112
null 103
Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists. 101
null 96
Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists 93
Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors 91
null 90
Design, Synthesis, and Pharmacological Properties of New Heteroarylpyridine/Heteroarylpyrimidine Derivatives as CB2 Cannabinoid Receptor Partial Agonists 84
null 84
null 83
Synthesis and Biological Evaluation of Novel 2-Amino-3-Aroyl-4-Neopentyl-5-Substituted Thiophene Derivatives as Allosteric Enhancers of the A1 Adenosine Receptor 79
Totale 7.389
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.759
Totale 30.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021431 0 0 0 0 0 54 28 79 28 121 62 59
2021/2022441 26 25 34 25 36 34 23 24 27 40 36 111
2022/2023438 41 59 8 67 58 55 37 33 47 2 21 10
2023/2024273 19 21 13 9 32 61 8 34 2 6 4 64
2024/20251.063 30 50 92 47 102 96 73 63 144 74 149 143
2025/20262.399 313 308 784 361 442 191 0 0 0 0 0 0
Totale 7.389